Ularitide Medicine 09 January 2018 Extended indication Heart failure; acute decompensated, 1st line Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Ularitide Domain Cardiovascular diseases Reason of inclusion Main indication Heart failure Extended indication Heart failure; acute decompensated, 1st line Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Cardiorentis Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Generieken voor 1e lijn reeds beschikbaar. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration 2018 Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Average 2 day / days Frequency of administration Dosage per administration 15 ng/kg/min References Clinical trial NCT01661634 Additional remarks continue infusie Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks